AbbVie (ABBV) Asset Writedowns and Impairment (2018 - 2024)

AbbVie (ABBV) has 4 years of Asset Writedowns and Impairment data on file, last reported at $4.5 billion in Q4 2024.

• Asset Writedowns and Impairment for Q4 2024 came in at $4.5 billion, up 218.58% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.5 billion (changed 0.0% YoY), and the FY2025 annual result was $847.0 million, down 81.08% from the prior year.
• Asset Writedowns and Impairment advanced to $4.5 billion in Q4 2024 per ABBV's latest filing, from $1.4 billion in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $4.5 billion in Q4 2024 and troughed at $80.0 million in Q2 2023.
• A 3-year average of $1.6 billion and a median of $1.1 billion in 2022 frame the typical range for Asset Writedowns and Impairment.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment soared 174.55% in 2023, then jumped 218.58% in 2024.
• A 3-year view of Asset Writedowns and Impairment shows it stood at $770.0 million in 2022, then surged by 82.47% to $1.4 billion in 2023, then jumped by 218.58% to $4.5 billion in 2024.
• Business Quant data shows ABBV's Asset Writedowns and Impairment at $4.5 billion in Q4 2024, $1.4 billion in Q4 2023, and $2.1 billion in Q3 2023.